News | July 31, 2024
Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Decision on EU marketing authorisation for this population expected by September 2024
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The inspections concluded with no Form 483 observations or significant critical findings
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Subscribe To Our Newsletter & Stay Updated
